In the last trading session, 13.04 million Pacific Biosciences of California Inc (NASDAQ:PACB) shares changed hands as the company’s beta touched 1.85. With the company’s per share price at $1.54 changed hands at -$0.1 or -6.10% during last session, the market valuation stood at $421.75M. PACB’s last price was a discount, traded about -295.45% off its 52-week high of $6.09. The share price had its 52-week low at $1.16, which suggests the last value was 24.68% up since then.
Analysts gave the Pacific Biosciences of California Inc (PACB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.19. If we narrow down to specifics, the data shows that 1 out of 11 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 4 recommended PACB as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Pacific Biosciences of California Inc’s EPS for the current quarter is expected to be -0.19.
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
Instantly PACB was in red as seen at the end of in last trading. With action 4.05%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -15.85%, with the 5-day performance at 4.05% in the green. However, in the 30-day time frame, Pacific Biosciences of California Inc (NASDAQ:PACB) is -14.92% down.
The consensus price target for the stock as assigned by Wall Street analysts is 3, meaning bulls need an upside of 48.67% from its current market value. According to analyst projections, PACB’s forecast low is 2 with 4 as the target high. To hit the forecast high, the stock’s price needs a -159.74% plunge from its current level, while the stock would need to soar -29.87% for it to hit the projected low.
Pacific Biosciences of California Inc (PACB) estimates and forecasts
Year-over-year growth is forecast to reach 5.07% up from the last financial year.
Consensus estimates given by 12 financial analysts project the company’s revenue in the current quarter to hit an average of 33.66M. 12 analysts are of the opinion that Pacific Biosciences of California Inc’s revenue for the current quarter will be 38.09M. The company’s revenue for the corresponding quarters a year ago was 38.81M and 36.01M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -13.26%. The estimates for the next quarter sales put growth at 5.78%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -15.31%. The 2025 estimates are for Pacific Biosciences of California Inc earnings to increase by 33.64%, but the outlook for the next 5-year period is at 24.02% per year.
Pacific Biosciences of California Inc (NASDAQ:PACB)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.6443% or 26.0 million shares worth $35.62 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF. With 21.16 shares estimated at $32.58 million under it, the former controlled 7.73% of total outstanding shares. On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF held about 4.43% of the shares, roughly 12.14 shares worth around $18.69 million.
